The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on clinicaltrials.gov.
For more information or questions about a study, please email email@example.com or call 312-355-5112.
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
Sponsor: National Cancer Institute
Principal Investigator: John Galvin, MD